Sales of 7 Celltrion products surpass ₩100 Billion in 1H

Company’s biosimilar portfolio shifts to next generation

7 of Celltrion’s 12 marketed products generated more than KRW 100 billion in first-half-year sales.

Sales of 2 of 3 existing products fall… 8 of 9 newer products post sales growth

Celltrion's recently launched products have become a major growth engine. In the first half of this year, sales from newer products exceeded those of legacy products by more than 60%. 8 of the company's 9 newer products recorded year-on-year sales growth, more than compensating for the stagnation of older products and driving overall revenue growth. The strong performance of higher-margin products also significantly improved profitability.

According to Celltrion on July 27, seven of its 12 marketed products generated more than KRW 100 billion in sales during the first half of the year.

The products are: Remsima, Truxima, Remsima SC, Yuflyma, Omlyclo, Stoboclo/Osenvelt, and Vegzelma.

Celltrion has obtained regulatory approvals in Europe and the US for Remsima, Herzuma, Truxima, Remsima SC, Zymfentra, Yuflyma, Vegzelma, Steqeyma, Stoboclo/Osenvelt, Omlyclo, Avtozma, and Eydenzelt.

Remsima is a biosimilar referencing the autoimmune disease therapy Remicade. Herzuma and Truxima are biosimilars of the oncology drugs Herceptin and MabThera, respectively. Remsima SC is a subcutaneous (SC) formulation developed by Celltrion by converting the original intravenous (IV) formulation of Remsima. In the US, Remsima SC received new drug approval under the brand name Zymfentra.

Yuflyma is a biosimilar version of the autoimmune therapy Humira. Vegzelma and Steqeyma reference the original drugs Avastin and Stelara, respectively. Stoboclo and Osenvelt are biosimilars of the bone disease therapies Prolia and Xgeva. Omlyclo is a biosimilar version of the allergy and asthma treatment Xolair, while Avtozma and Eydenzelt reference the original products Actemra and Eylea, respectively.

AI-generated image

The growth momentum of newer products significantly outpaced that of the legacy portfolio.

Celltrion classifies Remsima, Herzuma, and Truxima, which were launched during the early stages of its biosimilar business, as legacy products. Biologics introduced since 2020—including Remsima SC, Yuflyma, Vegzelma, Steqeyma, Stoboclo/Osenvelt, Omlyclo, Avtozma, and Eydenzelt—are categorized as newer products.

Sales from the newer portfolio rose 72.0% year over year to KRW 1.4061 trillion in the first half, up from KRW 817.3 billion a year earlier. In contrast, combined sales of the 3 legacy products edged down 0.4% to KRW 832.0 billion from KRW 835.3 billion. Sales of newer products exceeded those of legacy products by 69.0%, underscoring their role as the primary driver of the company's growth.

Among the three legacy products, only Truxima posted sales growth during the first half. Truxima generated KRW 288.8 billion in sales, up 24.8% year over year. Meanwhile, sales of Remsima and Herzuma declined 6.4% and 27.3%, respectively.

8 of the 9 newer products recorded higher sales in the first half of this year than last year.

Remsima SC generated KRW 356.7 billion in first-half sales, up 20.3% year over year. Yuflyma’s sales increased 21.4% to KRW 309.5 billion from KRW 254.9 billion generated last year.

Omlyclo and Stoboclo/Osenvelt reported eightfold and fifteenfold increases in sales, respectively, surpassing KRW 100 billion in half-year sales for the first time. Although Vegzelma's first-half sales declined 17.5% year over year to KRW 114.7 billion, it also exceeded the KRW 100 billion mark.

Newer products accounted for 65% of Celltrion's sales in the second quarter of this year, up from 53% in the same period last year.

The expanding contribution of newer products is directly enhancing the company’s profitability. Most of Celltrion's recently launched products are sold through the company's own direct sales infrastructure, a structure that delivers higher margins than sales conducted through overseas commercial partners.

In the first half, Celltrion posted operating profit of KRW 773.7 billion, up 97.4% year over year, while revenue increased 40.8% to KRW 2.5387 trillion. Its operating margin improved to 30.5% in H1 from 21.7% a year earlier, representing an increase of 8.8 percentage points year over year.